Tweet
Curr Drug Deliv
. 2020 Aug 27.
doi: 10.2174/1567201817666200827110445. Online ahead of print.
Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?
Iago Dillion Lima Cavalcanti 1 , Sandrelli Meridiana de F?tima Ramos Dos Santos Medeiros 1 , Daniel Charles Dos Santos Mac?do 1 , Isabella Mac?rio Ferro Cavalcanti 1 , Mariane Cajub? de Britto Lira Nogueira 1
Affiliations
- PMID: 32860358
- DOI: 10.2174/1567201817666200827110445
Abstract
In response to the global outbreak caused by SARS-CoV-2, this article aims to propose the development of nanosystems for the delivery of hydroxychloroquine in the respiratory system to the treatment of COVID-19. Performed a descriptive literature review, using the descriptors 'COVID-19', 'Nanotechnology', 'Respiratory Syndrome' and 'Hydroxychloroquine', in the PubMed, ScienceDirect and SciElo databases. After analyzing the articles according to the inclusion and exclusion criteria, they were divided into 3 sessions: Coronavirus: definitions, classifications and epidemiology, pharmacological aspects of hydroxychloroquine and pharmaceutical nanotechnology in targeting of drugs. We used 131 articles published until July 18, 2020. Hydroxychloroquine seems to promote a reduction in viral load, in vivo studies, preventing the entry of SARS-CoV-2 into lung cells, and the safety of its administration is questioned due to the toxic effects that it can develop, such as retinopathy, hypoglycemia and even cardiotoxicity. Nanosystems for the delivery of drugs in the respiratory system may be a viable alternative for the administration of hydroxychloroquine, which may enhance the therapeutic effect of the drug with a consequent decrease in its toxicity, providing greater safety for implementation in the clinic in the treatment of COVID-19.
Keywords: COVID-19; Hydroxychloroquine.; Nanotechnology; Respiratory Syndrome; SARS-CoV-2.